Amgen Inc. (NASDAQ:AMGN) Shares Acquired by O Keefe Stevens Advisory Inc.

O Keefe Stevens Advisory Inc. increased its stake in Amgen Inc. (NASDAQ:AMGN) by 1.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 48,008 shares of the medical research company’s stock after acquiring an additional 457 shares during the quarter. Amgen makes up about 3.9% of O Keefe Stevens Advisory Inc.’s portfolio, making the stock its 8th biggest holding. O Keefe Stevens Advisory Inc.’s holdings in Amgen were worth $12,513,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the stock. Capital Performance Advisors LLP acquired a new position in shares of Amgen during the 3rd quarter worth approximately $25,000. Hershey Financial Advisers LLC purchased a new position in Amgen during the second quarter worth approximately $30,000. Legacy Investment Solutions LLC purchased a new position in Amgen during the third quarter worth approximately $29,000. Matrix Trust Co acquired a new position in Amgen during the third quarter worth $36,000. Finally, Livelsberger Financial Advisory purchased a new stake in Amgen in the 3rd quarter valued at $56,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Up 1.0 %

NASDAQ AMGN opened at $272.11 on Friday. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The firm has a 50 day moving average of $275.01 and a two-hundred day moving average of $307.49. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The stock has a market capitalization of $146.27 billion, a PE ratio of 34.84, a price-to-earnings-growth ratio of 2.68 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same quarter in the previous year, the firm posted $4.96 earnings per share. The company’s revenue was up 23.2% compared to the same quarter last year. As a group, research analysts expect that Amgen Inc. will post 19.57 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.50%. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio is 115.24%.

Wall Street Analyst Weigh In

Several research firms have weighed in on AMGN. Wolfe Research initiated coverage on shares of Amgen in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Piper Sandler Companies reissued an “overweight” rating and set a $310.00 target price on shares of Amgen in a research note on Thursday, January 2nd. Sanford C. Bernstein started coverage on Amgen in a research note on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $405.00 price objective on shares of Amgen in a research report on Tuesday, October 22nd. Finally, Redburn Partners decreased their target price on shares of Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $314.91.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.